| 12/13/2023 | BKGNIG | S&P lowers Pfizer
|
| 12/13/2023 | BKGNIG | Moody’s prunes Pfizer
|
| 11/1/2023 | BKBWEMGNIG | Pfizer revenues fall significantly; Covid products see sharp decline
|
| 3/13/2023 | BKBWGNIG | Pfizer expects unchanged IG ratings from $31 billion acquisition debt
|
| 8/16/2021 | BKGNIG | S&P rates Pfizer notes A+
|
| 8/16/2021 | BKGNIG | Moody's assigns A2 to Pfizer notes
|
| 11/16/2020 | BKGNIG | S&P lowers Pfizer
|
| 11/16/2020 | BKGNIG | Moody’s downgrades Pfizer
|
| 6/17/2020 | BK | Upjohn gets revolver, term loan as Mylan combination moves forward
|
| 6/15/2020 | BKIG | S&P rates Upjohn notes BBB-
|
| 5/21/2020 | BKGNIG | Fitch rates Pfizer notes A
|
| 5/18/2020 | BKGNIG | Moody's gives Pfizer notes A1
|
| 5/18/2020 | BKGNIG | S&P rates Pfizer notes AA-
|
| 3/25/2020 | BKGNIG | Moody's assigns Pfizer notes A1
|
| 3/25/2020 | BKGNIG | S&P rates Pfizer notes AA-
|
| 6/17/2019 | BKBWIG | Pfizer to use mostly debt, some cash to buy Array for $11.4 billion
|
| 3/5/2019 | BKIGLM | Pfizer to refinance, redeem or buy back debt via $5 billion issue
|
| 2/5/2015 | BKIG | Pfizer plans debt financing for $17 billion acquisition of Hospira
|
